GlaxoSmithKline R&D vet Min Li nabs $100M to launch a Bob Nelsen-backed startup focused on China’s burgeoning neuro market
In recent years we’ve seen a whole string of China-based biotech startups gain impressive backing as they kickstarted new companies with big plans in oncology as they created pipelines and inked international licensing deals. Now GSK R&D vet and former Johns Hopkins professor Min Li plans to take much the same page on strategy and start something big in neuro. And for now, he has this particular field in China largely to himself.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,200+ biopharma pros reading Endpoints daily — and it's free.